In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Analysts say the drug could emerge as a potential competitor to Merck’s blockbuster immunotherapy Keytruda. Keytruda is ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

No, Keytruda isn’t a chemotherapy drug. It’s an immunotherapy drug. Chemotherapy is a type of cancer treatment that kills cancer cells or stops them from multiplying (making more cells).

versus first-line treatment with Keytruda (pembrolizumab) plus chemotherapy. Findings, demonstrated by the phase 2 PERLA ...

Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the ...

Patients with bone-predominant metastatic renal cell carcinoma (RCC) appeared to have better outcomes when they started ...

LOUISVILLE, Ky. -- Large tumor size and high disease grade were associated with an increased risk of early cancer-related ...

Merck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with ...

Media ReleaseMature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and ...